National Vision (EYE)
(Delayed Data from NSDQ)
$10.04 USD
+0.07 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.02 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.04 USD
+0.07 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.02 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 8.70% and 95.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors continue to remain optimistic about National Vision (EYE) due to the expansion of stores and new investments for the improved optometric experience.
National Vision (EYE) Plans to Open New Stores Amid Macro Woes
by Zacks Equity Research
National Vision (EYE) plans to continue executing core growth initiatives and further investing in competitive advantages.
National Vision (EYE) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) Q1 net revenues are positively impacted by the timing of unearned revenue.
National Vision (EYE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 63.16% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 14.63% and 3.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for National Vision (EYE) This Earnings Season?
by Zacks Equity Research
National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate National Vision (EYE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -22.22% and 8.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
National Vision's (EYE) share price is likely to grow following the company's efforts to expand remote capabilities and investments in doctor recruiting and retention efforts.
National Vision (EYE) Rides on Comps Growth Amid Macro Issues
by Zacks Equity Research
National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.
EYE vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. RMD: Which Stock Is the Better Value Option?
Should Value Investors Buy National Vision (EYE) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
National Vision (EYE) Q4 Revenues Miss Mark, Margins Down
by Zacks Equity Research
National Vision (EYE) is facing a challenging macroeconomic environment, which negatively impacted its performance in the fourth quarter of 2022.
National Vision (EYE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of -33.33% and 0.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zevia (ZVIA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevia (ZVIA) delivered earnings and revenue surprises of 16.67% and 15.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 142.14% and 2.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of -12.24% and 1.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Investors Undervaluing National Vision (EYE) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 25.71% and 0.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 2,000% and 26.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 22.22% and 6.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Q3 Earnings Top Mark, Margins Down
by Zacks Equity Research
National Vision (EYE) is facing demand headwinds across its network of stores due to the constraints on eye exam capacity.
National Vision (EYE) Q3 Earnings Beat Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 87.50% and 0.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy National Vision (EYE) Ahead of Earnings?
by Zacks Equity Research
National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.